drugset

drugset / Trial / NCT05219500

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

NCT05219500 ↗

Phase 2 Active not recruiting 115 enrolled Fusion Pharmaceuticals Inc.

NaSingle-groupOpen-labelTreatment

Summary

The treatment regimen will consist of 4 doses of FPI-2265

Timeline

Start: 2021-12-16
Primary completion: 2025-05-30
Completion: 2026-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FPI-2265	Small molecule	0.1 mbq/kg	—

Indications